This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ olanzapine,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Treatment of Schizophrenia: Olanzapine is effective in managing the symptoms of schizophrenia, including hallucinations, delusions, disorganized thinking, and emotional disturbances. It helps stabilize mood and improve overall functioning in individuals with this condition.

  2. Management of Bipolar Disorder: Olanzapine is used in combination with other medications to treat acute manic or mixed episodes associated with bipolar disorder. It can help control symptoms such as elevated mood, agitation, irritability, and impulsivity.

  3. Maintenance Therapy for Bipolar Disorder: Olanzapine may also be prescribed as a maintenance treatment to prevent recurrence of manic or mixed episodes in patients with bipolar disorder.

  4. Agitation and Aggression: Olanzapine can be used to manage agitation and aggression in various psychiatric conditions, including schizophrenia and bipolar disorder. It helps to calm patients and reduce the risk of harm to themselves or others.

  5. Anxiety Disorders: Olanzapine may be prescribed off-label for the treatment of anxiety disorders, particularly when other medications have been ineffective. It can help alleviate symptoms of anxiety and promote relaxation in some individuals.

  6. Augmentation Therapy: Olanzapine is sometimes used as an augmentation strategy in the treatment of depression, especially in cases where standard antidepressants have not provided sufficient relief. It may help improve mood and reduce symptoms of depression when combined with other medications.

  7. Sleep Disorders: Olanzapine can be prescribed off-label to manage sleep disturbances, particularly in individuals with psychiatric disorders such as schizophrenia or bipolar disorder. It may help improve sleep quality and duration in some patients.

  8. Tourette Syndrome: Olanzapine may be used off-label to manage tics and behavioral symptoms associated with Tourette syndrome, a neurological disorder characterized by involuntary movements and vocalizations.

  9. Side Effects: Common side effects of olanzapine may include drowsiness, weight gain, increased appetite, dry mouth, constipation, dizziness, and orthostatic hypotension (drop in blood pressure upon standing). Long-term use may be associated with metabolic changes, including elevated blood sugar levels and lipid abnormalities.

  10. Rare but Serious Side Effects: Olanzapine may also be associated with rare but serious side effects such as neuroleptic malignant syndrome (NMS), tardive dyskinesia (involuntary movements), and agranulocytosis (severe reduction in white blood cell count). Patients should be monitored regularly for these potential complications.

  11. Pregnancy and Breastfeeding: Olanzapine should be used with caution during pregnancy and breastfeeding, as its safety in these situations is not well-established. The potential risks and benefits should be carefully weighed by healthcare providers when considering its use in pregnant or breastfeeding women.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of olanzapine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Lactobacillus acidophilus Increases
species Lactobacillus crispatus Increases
species Lactobacillus gasseri Increases
species Lactobacillus helveticus Increases
species Lactobacillus jensenii Increases
species Lactobacillus johnsonii Increases
species Lactobacillus kefiranofaciens Increases

Bacteria Impacted by olanzapine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Lactobacillaceae family Increases
0 1 Roseburia genus Decreases
1 0 Caenorhabditis genus Decreases
0 1 Agathobacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Eggerthella genus Decreases
0 1 Lachnospira genus Decreases
0 1 Phocaeicola genus Decreases
1 0 Akkermansia genus Decreases
0 1 Thomasclavelia genus Decreases
1 0 Lactobacillus genus Increases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
0 1 environmental samples no rank Increases
0 1 unclassified Lactobacillus no rank Increases
1 0 Agathobacter rectalis species Decreases
1 0 Eggerthella lenta species Decreases
1 0 Akkermansia muciniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Caenorhabditis briggsae species Decreases
0 1 Caenorhabditis elegans species Decreases
0 1 Caenorhabditis inopinata species Decreases
0 1 Caenorhabditis remanei species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Roseburia intestinalis species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Phocaeicola vulgatus species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Lactobacillus ultunensis species Increases
0 1 Lactobacillus helveticus species Increases
0 1 Lactobacillus johnsonii species Increases
0 1 Lactobacillus kefiranofaciens species Increases
0 1 Lactobacillus amylolyticus species Increases
0 1 Lactobacillus acetotolerans species Increases
0 1 Lactobacillus amylovorus species Increases
0 1 Lactobacillus iners species Increases
0 1 Lactobacillus taiwanensis species Increases
0 1 Lactobacillus crispatus species Increases
0 1 Lactobacillus intestinalis species Increases
0 1 Lactobacillus acidophilus species Increases
0 1 Lactobacillus paragasseri species Increases
0 1 Lactobacillus jensenii species Increases
0 1 [Lactobacillus] rogosae species Increases
0 1 ATCC 15434 species Increases
0 1 Lactobacillus alvei species Increases
0 1 Lactobacillus animata species Increases
0 1 Lactobacillus apis species Increases
0 1 Lactobacillus bombicola species Increases
0 1 Lactobacillus brevisimilis species Increases
0 1 Lactobacillus equicursoris species Increases
0 1 Lactobacillus faeni species Increases
0 1 Lactobacillus fornicalis species Increases
0 1 Lactobacillus gallinarum species Increases
0 1 Lactobacillus gigeriorum species Increases
0 1 Lactobacillus guizhouensis species Increases
0 1 Lactobacillus hamsteri species Increases
0 1 Lactobacillus helsingborgensis species Increases
0 1 Lactobacillus hominis species Increases
0 1 Lactobacillus intermedius species Increases
0 1 Lactobacillus japonicus species Increases
0 1 Lactobacillus kalixensis species Increases
0 1 Lactobacillus kitasatonis species Increases
0 1 Lactobacillus kullabergensis species Increases
0 1 Lactobacillus leichmannii species Increases
0 1 Lactobacillus letivazi species Increases
0 1 Lactobacillus mulieris species Increases
0 1 Lactobacillus panisapium species Increases
0 1 Lactobacillus pasteurii species Increases
0 1 Lactobacillus psittaci species Increases
0 1 Lactobacillus rodentium species Increases
0 1 Lactobacillus selangorensis species Increases
0 1 Lactobacillus sp. 7_1_47FAA species Increases
0 1 Lactobacillus sp. MYMRS/TEN2 species Increases
0 1 Lactobacillus terrae species Increases
0 1 Lactobacillus delbrueckii species Increases
1 0 Lactobacillus gasseri species Increases
0 1 Lactobacillus casei group species group Increases
0 1 Lactobacillus gasseri ATCC 33323 = JCM 1131 strain Increases
0 1 Lactobacillus gasseri DSM 14869 strain Increases
0 1 Lactobacillus gasseri 202-4 strain Increases
0 1 Peloderinae subfamily Decreases

Impact of olanzapine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 1 1
ADHD 1.4 0.3 3.67
Age-Related Macular Degeneration and Glaucoma 0.5 0.5
Allergic Rhinitis (Hay Fever) 1 0.1 9
Allergies 1.2 1.9 -0.58
Allergy to milk products 0.6 0.3 1
Alzheimer's disease 1.8 2.7 -0.5
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.5 0.9 -0.8
Ankylosing spondylitis 1.5 0.6 1.5
Anorexia Nervosa 1.4 -1.4
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 2.3 1.9 0.21
Atherosclerosis 0.3 1.6 -4.33
Atrial fibrillation 0.9 1.5 -0.67
Autism 2.6 3 -0.15
Autoimmune Disease 0.7 0.5 0.4
benign prostatic hyperplasia 0.3 -0.3
Bipolar Disorder 0.6 0.8 -0.33
Brain Trauma 0.6 0.8 -0.33
Cancer (General) 0.6 0.6
Carcinoma 0.6 0.9 -0.5
Celiac Disease 1 1.3 -0.3
Cerebral Palsy 0.4 0.8 -1
Chronic Fatigue Syndrome 1.6 0.9 0.78
Chronic Kidney Disease 1.3 1.6 -0.23
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 1.4 -1.4
Chronic Urticaria (Hives) 0.3 -0.3
Coagulation / Micro clot triggering bacteria 0.5 -0.5
Cognitive Function 1.6 1.3 0.23
Colorectal Cancer 3.1 2.8 0.11
Constipation 1.2 0.5 1.4
Coronary artery disease 0.9 1.5 -0.67
COVID-19 2.2 3.4 -0.55
Crohn's Disease 1.9 2.8 -0.47
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.8 -0.8
d-lactic acidosis (one form of brain fog) 1.3 -1.3
deep vein thrombosis 0.7 0.8 -0.14
Denture Wearers Oral Shifts 0.6 0.6
Depression 3.5 4.2 -0.2
Eczema 0.2 0.2
Endometriosis 1.2 1.4 -0.17
Epilepsy 1 0.7 0.43
erectile dysfunction 0.5 0.5
Fibromyalgia 1.7 1.4 0.21
Functional constipation / chronic idiopathic constipation 1.2 0.8 0.5
gallstone disease (gsd) 0.6 0.8 -0.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.6 0.3 1
Generalized anxiety disorder 0.7 1 -0.43
Gout 0.5 0.1 4
Graves' disease 0.9 1.4 -0.56
Gulf War Syndrome 0.4 -0.4
Halitosis 0.3 0.3
Hashimoto's thyroiditis 1.7 0.7 1.43
Heart Failure 0.9 1.9 -1.11
Hidradenitis Suppurativa 0.6 0.6
High Histamine/low DAO 0.5 0.6 -0.2
hypercholesterolemia (High Cholesterol) 0.3 -0.3
hyperglycemia 1.2 0.7 0.71
Hyperlipidemia (High Blood Fats) 1 1
hypertension (High Blood Pressure 1.6 1.6 0
Hypothyroidism 0.1 0.3 -2
Hypoxia 1 0.6 0.67
IgA nephropathy (IgAN) 1.2 0.6 1
Inflammatory Bowel Disease 2.2 3.1 -0.41
Insomnia 0.4 2.6 -5.5
Intelligence 0.3 0.3
Intracranial aneurysms 0.9 0.9
Irritable Bowel Syndrome 1.9 2.2 -0.16
ischemic stroke 0.4 1.7 -3.25
Liver Cirrhosis 2.3 2.5 -0.09
Long COVID 2.2 2.4 -0.09
Low bone mineral density 0.8 -0.8
Lung Cancer 0.3 -0.3
ME/CFS with IBS 0.3 -0.3
ME/CFS without IBS 0.7 0.3 1.33
Menopause 0.7 0.7 0
Metabolic Syndrome 1.9 2.1 -0.11
Mood Disorders 3.7 4.4 -0.19
multiple chemical sensitivity [MCS] 0.1 0.6 -5
Multiple Sclerosis 2.2 2.1 0.05
Multiple system atrophy (MSA) 0.4 0.6 -0.5
myasthenia gravis 0.5 -0.5
neuropathic pain 0.3 1.3 -3.33
Neuropathy (all types) 0.4 1.1 -1.75
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2 3 -0.5
NonCeliac Gluten Sensitivity 1.5 0.3 4
Obesity 3 3 0
obsessive-compulsive disorder 1.2 0.9 0.33
Osteoarthritis 0.5 0.4 0.25
Osteoporosis 1.8 1.2 0.5
pancreatic cancer 0.3 -0.3
Parkinson's Disease 3 3.3 -0.1
Polycystic ovary syndrome 1.4 1.6 -0.14
primary biliary cholangitis 0.6 -0.6
Primary sclerosing cholangitis 0.3 0.6 -1
Psoriasis 0.3 2.4 -7
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.3 2.2 0.05
Rosacea 0.6 0.5 0.2
Schizophrenia 1.9 2.6 -0.37
scoliosis 0 0
Sjögren syndrome 0.8 -0.8
Sleep Apnea 0.3 1.1 -2.67
Slow gastric motility / Gastroparesis 0.9 0.9
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.6 -1
Stress / posttraumatic stress disorder 1 2.2 -1.2
Systemic Lupus Erythematosus 1.4 1.4 0
Tic Disorder 0 0
Tourette syndrome 0.7 0.3 1.33
Type 1 Diabetes 1.2 1.7 -0.42
Type 2 Diabetes 2.5 2.1 0.19
Ulcerative colitis 1.7 2.1 -0.24
Unhealthy Ageing 1.3 1.9 -0.46
Vitiligo 0.6 0.1 5

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]